Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-[4-(2-Oxo-2-phenyethyl)phenyl]guanidine is a small molecule compound characterized chemically as a guanidine derivative attached to a phenacyl group. It belongs to the class of stilbenes, organic compounds containing a 1,2-diphenylethylene moiety. The molecular formula is C15H15N3O with an average molecular weight of approximately 253.3 g/mol. Mechanistically, it acts as an inhibitor of urokinase-type plasminogen activator (uPA), which plays roles in processes such as fibrinolysis and tissue remodeling. This inhibition suggests potential utility in modulating proteolytic activity related to disease states involving uPA. The compound is experimental and has not been approved for clinical use or marketed under any brand names. There are no known clinical trials or approved indications associated with this drug at present.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine.